Cargando…
The Therapeutic Index as Indicated by Efficacy/Safety Ratio May Be Primarily Assessed by Meta-Analysis of the Efficacy of ICS Combination Therapy for COPD [Letter]
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234182/ https://www.ncbi.nlm.nih.gov/pubmed/35769224 http://dx.doi.org/10.2147/COPD.S373924 |
| _version_ | 1784736004514512896 |
|---|---|
| author | Teramoto, Shinji |
| author_facet | Teramoto, Shinji |
| author_sort | Teramoto, Shinji |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9234182 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Dove |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92341822022-06-28 The Therapeutic Index as Indicated by Efficacy/Safety Ratio May Be Primarily Assessed by Meta-Analysis of the Efficacy of ICS Combination Therapy for COPD [Letter] Teramoto, Shinji Int J Chron Obstruct Pulmon Dis Letter Dove 2022-06-22 /pmc/articles/PMC9234182/ /pubmed/35769224 http://dx.doi.org/10.2147/COPD.S373924 Text en © 2022 Teramoto. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
| spellingShingle | Letter Teramoto, Shinji The Therapeutic Index as Indicated by Efficacy/Safety Ratio May Be Primarily Assessed by Meta-Analysis of the Efficacy of ICS Combination Therapy for COPD [Letter] |
| title | The Therapeutic Index as Indicated by Efficacy/Safety Ratio May Be Primarily Assessed by Meta-Analysis of the Efficacy of ICS Combination Therapy for COPD [Letter] |
| title_full | The Therapeutic Index as Indicated by Efficacy/Safety Ratio May Be Primarily Assessed by Meta-Analysis of the Efficacy of ICS Combination Therapy for COPD [Letter] |
| title_fullStr | The Therapeutic Index as Indicated by Efficacy/Safety Ratio May Be Primarily Assessed by Meta-Analysis of the Efficacy of ICS Combination Therapy for COPD [Letter] |
| title_full_unstemmed | The Therapeutic Index as Indicated by Efficacy/Safety Ratio May Be Primarily Assessed by Meta-Analysis of the Efficacy of ICS Combination Therapy for COPD [Letter] |
| title_short | The Therapeutic Index as Indicated by Efficacy/Safety Ratio May Be Primarily Assessed by Meta-Analysis of the Efficacy of ICS Combination Therapy for COPD [Letter] |
| title_sort | therapeutic index as indicated by efficacy/safety ratio may be primarily assessed by meta-analysis of the efficacy of ics combination therapy for copd [letter] |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234182/ https://www.ncbi.nlm.nih.gov/pubmed/35769224 http://dx.doi.org/10.2147/COPD.S373924 |
| work_keys_str_mv | AT teramotoshinji thetherapeuticindexasindicatedbyefficacysafetyratiomaybeprimarilyassessedbymetaanalysisoftheefficacyoficscombinationtherapyforcopdletter AT teramotoshinji therapeuticindexasindicatedbyefficacysafetyratiomaybeprimarilyassessedbymetaanalysisoftheefficacyoficscombinationtherapyforcopdletter |